Skip to main content
Michael Bozik, MD, Neurology, Pittsburgh, PA

MichaelEdwardBozikMD

Neurology • Pittsburgh, PA

Neurooncology

President and CEO, Knopp Biosciences

Join to view full profile

Dr. Bozik is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Bozik's full profile

Already have an account?

Education & Training

  • UPMC Medical Education (Pittsburgh)
    UPMC Medical Education (Pittsburgh)Residency, Neurology, 1990 - 1992
  • UPMC Medical Education
    UPMC Medical EducationResidency, Pathology-Anatomic and Clinical, 1989 - 1990
  • University of Michigan Health System
    University of Michigan Health SystemResidency, Neurology, 1988 - 1989
  • UPMC Medical Education (Mercy)
    UPMC Medical Education (Mercy)Internship, Transitional Year, 1987 - 1988
  • University of Pittsburgh School of Medicine
    University of Pittsburgh School of MedicineClass of 1987

Certifications & Licensure

  • PA State Medical License
    PA State Medical License 1989 - 2014
  • American Board of Psychiatry and Neurology Neurology

Publications & Presentations

PubMed

Press Mentions

  • Knopp Biosciences Presents New Phase 2 Data at AAAAI 2022 Demonstrating That Oral Dexpramipexole Improves Airflow Obstruction as Measured by Forced Expiry Volume (FEV1), Largely Through Its Effect on Forced Vital Capacity (FVC)
    Knopp Biosciences Presents New Phase 2 Data at AAAAI 2022 Demonstrating That Oral Dexpramipexole Improves Airflow Obstruction as Measured by Forced Expiry Volume (FEV1), Largely Through Its Effect on Forced Vital Capacity (FVC)February 28th, 2022
  • Knopp Biosciences Presents New Phase 2 Data at ERS 2021 Demonstrating That Reduction in Eosinophil Count by Dexpramipexole Significantly Correlates with Improvement in Lung Function
    Knopp Biosciences Presents New Phase 2 Data at ERS 2021 Demonstrating That Reduction in Eosinophil Count by Dexpramipexole Significantly Correlates with Improvement in Lung FunctionSeptember 7th, 2021
  • Knopp Biosciences Reports Positive Results from the Phase 2 EXHALE Trial of Oral Dexpramipexole in Moderate-to-Severe Eosinophilic Asthma at ATS 2021
    Knopp Biosciences Reports Positive Results from the Phase 2 EXHALE Trial of Oral Dexpramipexole in Moderate-to-Severe Eosinophilic Asthma at ATS 2021May 17th, 2021
  • Join now to see all

Grant Support

  • Therapeutic Studies--Primary CNS MalignanciesNational Cancer Institute1996–1997
  • Immunobiological Responses To RAT Brain Tumor VaccinesNational Cancer Institute1996–1997

Dr. Michael Bozik, Dr. Michael Bozik, MD, Dr. M Bozik, Dr. Michael Edward Bozik